Rising Prevalence of Multiple Sclerosis in Switzerland - Results from the Swiss Multiple Sclerosis Registry
Neuroepidemiology · 2024
DOI: 10.1159/000542632 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuroepidemiology, 2024. Verfasst von Stefania Iaquinto und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Multiple Sclerosis, Registries. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Understanding the prevalence of multiple sclerosis (MS) provides information for healthcare planning and helps identify trends and patterns of disease occurrence. For Switzerland, the number of persons with MS (pwMS) was last estimated at approximately 15,000 in 2016. The study’s objectives are to update estimates of MS prevalence and characterise the change in MS prevalence in Switzerland between 2016 and 2021, the last year with complete administrative data.
Methods
The Swiss MS Registry (SMSR) is an ongoing, longitudinal study in Switzerland. It has previously established a methodology to assess the epidemiology of MS in Switzerland by integrating SMSR data with administrative data on reimbursement approvals for disease-modifying therapies (DMTs). Subsequently, the benchmark-multiplier method is applied to the combined data. Using the same methodology, we calculated overall and sex- and age-specific prevalence rates for 2021. Furthermore, we descriptively analysed changes since 2016 by comparing the prevalence figures and demographic and clinical characteristics of pwMS in both years.
Results
We estimated the population of pwMS in Switzerland at 18,140 [95% simulation interval 17,550-18,750], corresponding to a period prevalence of 200.8-214.5/100,000 inhabitants. Peak prevalence was observed in the 50 to 55-year age group. Compared to 2016, the 2021 estimate corresponds to a 20% increase (n=3,000). Extrapolating from Swiss population growth, we estimated that one-fifth of the observed prevalence increase may be attributed to a rising population. The proportion of pwMS in the age range from 50 to 64 (32.5% vs. 35.9%) and above 65 (8.0% vs. 11.1%) years increased. Consequently, the median [interquartile range] age increased from 47 [37-55] to 49 [38-57] years. The median age at diagnosis (36 [28-45] years) and the female-to-male ratio (2.7:1) remained stable since 2016. The proportion of pwMS treated with DMTs increased from 62.1% to 69.0%, with the largest change observed in infusion therapies (15.7% vs. 23.3%).
Conclusion
The estimated MS prevalence in Switzerland has increased since the previous estimate in 2016, with a shift in peak prevalence towards older ages. Population growth explained around one-fifth of this increase, thus leaving room for contributions by additional factors, which require further investigation. The rising MS prevalence has several implications for healthcare, research and society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
- Department of Neurology, Inselspital, University Hospital Bern and University of Bern, Bern, Switzerland.
- Department of Neurology, Schulthess Clinic, Zurich, Switzerland.
- Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.
- Institute for Implementation Science in Health Care, University of Zurich, Zurich, Switzerland.
- Center for Reproducible Science (CRS), University of Zurich, Zurich, Switzerland.
Zitieren
APA
Iaquinto, S., Chan, A., Manjaly, Z. M., Stanikić, M., Ineichen, B. V., Kuhle, J., Haag, C., Müller, J., Yaldizli, Ö., Kamm, C. P., Calabrese, P., Zecca, C., Magnusson, T., Ammann, S., Kesselring, J., Baum, C., Kaminski, M., Puhan, M. A., & von Wyl, V. (2024). Rising Prevalence of Multiple Sclerosis in Switzerland - Results from the Swiss Multiple Sclerosis Registry. Neuroepidemiology. https://doi.org/10.1159/000542632
Vancouver
Iaquinto S, Chan A, Manjaly ZM, Stanikić M, Ineichen BV, Kuhle J, et al. Rising Prevalence of Multiple Sclerosis in Switzerland - Results from the Swiss Multiple Sclerosis Registry. Neuroepidemiology. 2024. doi:10.1159/000542632
BibTeX
@article{Iaquinto2024,
author = {Iaquinto, Stefania and Chan, Andrew and Manjaly, Zina-Mary and Stanikić, Mina and Ineichen, Benjamin Victor and Kuhle, Jens and Haag, Christina and Müller, Jannis and Yaldizli, Özgür and Kamm, Christian Philipp and Calabrese, Pasquale and Zecca, Chiara and Magnusson, Tomas and Ammann, Sabin and Kesselring, Jürg and Baum, Claudia and Kaminski, Miriam and Puhan, Milo Alan and von Wyl, Viktor},
title = {Rising Prevalence of Multiple Sclerosis in Switzerland - Results from the Swiss Multiple Sclerosis Registry},
journal = {Neuroepidemiology},
year = {2024},
doi = {10.1159/000542632}
}
EUVIMED